Iclusig is an anti-chronic myeloid leukemia drug owned by Takeda Pharmaceuticals USA. It contains the active ingredient ponatinib hydrochloride, and was first authorized for market use on December 14, 2012. The drug is available in tablet form for oral administration.
The generic version of Iclusig may be available after December 12, 2033 following the expiry of the last patent. The release of Iclusig's generic version is dependent on the patents held by Takeda Pharmaceuticals USA.
Iclusig is used in the treatment of various types of leukemia, particularly Philadelphia chromosome positive acute lymphoblastic leukemia, chronic myeloid leukemia, and leukemia resulting from a mutation in the BCR-ABL kinase domain.
Iclusig, owned by Takeda Pharmaceuticals USA, is protected by 6 patents, none of which have expired. The last patent is due to expire on December 12, 2033 allowing for possible release of Iclusig generic. Below are the details of the patent: